http://nz.biz.yahoo.com//091022/24/f953.html
Research and Markets (http://www.researchandmarkets.com/research/72532e/thailand_pharmaceu)
has announced the addition of the "Thailand
Pharmaceuticals and Healthcare Report Q4 2009" report to their
offering.
The Thailand Pharmaceuticals and Healthcare Report provides industry
professionals and strategists, corporate analysts, pharmaceutical
associations, government departments and regulatory bodies with
independent forecasts and competitive intelligence on Thailand's
pharmaceuticals and healthcare industry
For the Q4 2009 update of the Thailand Pharmaceuticals & Healthcare
Report, we have extended our forecasts for prescription pharmaceuticals,
patented products, generic drugs and over-the-counter (OTC) medicines
through to 2018. The South East Asian country's US$3.52bn pharmaceutical
market is projected to post a compound annual growth rate (CAGR) of
8.20% in local currency terms. Due to the strengthening of the baht over
the next 10 years, the market will post a CAGR of 10.37% in US dollar
terms. However, we must caution that there are significant risks to this
optimistic forecast, primarily political instability.
In the Pharmaceutical Environment Ratings table for Q409, Thailand has
improved by one position, from 10th to 9th, out of the 15 key markets
surveyed in the Asia Pacific region. Thailand's growing and ageing
population represents a substantial commercial opportunity for
drugmakers, although its controversial compulsory licensing scheme is
deterring foreign investment.
Thailand's reputation for over-medicating has been highlighted once
again. During the swine flu outbreak in July 2009, it was announced that
the country would import second-line antivirals, such as zanamivir,
amantadine and rimantadine. These would be in addition to oseltamivir,
which was increasingly associated with resistance to the H1N1 virus in
other parts of the world. In the World Health Organization (WHO)'s study
on oseltamivir resistance during the 2007-2008 flu season, Thailand was
named as one of the countries with a high antiviral drug resistance rate.
The Burden of Disease Database (BoDD) reveals that Thailand will become
unhealthier over the next 20 years. The number of disability-adjusted
life years (DALYs) lost to non-communicable disease will increase from
6,518,798 in 2008 to 8,438,723 in 2030, a rise of 29%. Meanwhile, the
number of DALYs lost to communicable disease will increase from
3,526,188 in 2008 to 5,303,347, a rise of 50%. The main driver of these
increases is a growing and ageing population.
Thailand's GDP is expected to contract by -4.5% in real terms during
2009, from THB9,103bn (US$267bn) to THB8,813bn (US$253bn). This means
that both state and patients will have less money to spend on
healthcare. Partial economic recovery is forecast for 2009/2010, with
full growth returning the following year. Pharmaceutical sales will
rebound slightly in 2010, but then slowly decrease over our 10- year
forecast period. It must be noted however that Thailand's projected
growth is still one of the highest in our 71-market coverage universe,
and above the average for Asia Pacific. By 2018, the value of annual
pharmaceutical sales in Thailand will have reached just under US$10bn.
Key Topics Covered:
Executive Summary
Swot Analysis
Pharmaceutical Business Environment Ratings
Thailand - Market Summary
Regulatory Regime
Industry Trends And Developments
Industry Forecast Scenario
Competitive Landscape
Company Profiles
Country Snapshot: Thailand Demographic Data
Bmi Methodology
Companies Mentioned:
Pfizer
Sanofi-Aventis
GlaxoSmithKline
Merck & Co
Domestic Manufacturer Profiles
Siam Pharmaceutical
Government Pharmaceutical Organisation (GPO)
Biolab
For more information visit http://www.researchandmarkets.com/research/72532e/thailand_pharmaceu
Contact:Research and MarketsLaura Wood, Senior Manager,press@researchandmarkets.comU.S.
Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
|
